Welcome - Register - Login - Help/FAQ - 0 items

Search
Enter keywords, a title or
a report id number below.

Advanced


	Select a currency for use throughout the site

Viewing report

Order by Fax
Ask a Question
Printer Friendly
PDF Brochure

Electronic (PDF)
Site License
Enterprisewide

Live Chat Live Help Software for Website

Jevtana (Cabazitaxel) - Positive Recommendation in the EU for Metastatic Castration-Resistant Prostate Cancer

GlobalData, March 2011, Pages: 5


	Description



		Table of Contents


		Enquire before Buying


		Send to a Friend

Jevtana (Cabazitaxel) - Positive Recommendation in the EU for Metastatic Castration-Resistant Prostate Cancer

Summary

GlobalData’s report, “Jevtana (Cabazitaxel) - Positive Recommendation in the EU for Metastatic Castration-Resistant Prostate Cancer” provides key information on current available treatment of Prostate cancer, drivers and barriers for the future Prostate cancer market and how the novel pipeline molecules will drive the global market

Scope

- Data and information on the positive recommendations of Jevtana (Cabazitaxel) in the EU for metastatic castration-resistant prostate Cancer

Reasons to buy

- Develop business strategies by understanding the trends and developments in Prostate cancer market

For enquiries please call us on:

+353-1-415-1241 (GMT Office Hours)

1-800-526-8630 (US/Canada Toll Free)

1-917-300-0470 (EST Office Hours)